2008-07-02 20:27:17 - www.companiesandmarkets.com adds new report - Indevus Pharmaceuticals - Premium Company Profile

www.companiesandmarkets.com/Summary-Company-Profile/Indevus-Phar ..
Introduction

Indevus Pharmaceuticals is a biopharmaceutical company focused on obtaining product candidates and product from other pharmaceutical and biotechnology companies through collaboration, in licensing and acquisitions. The company´s acquisition of Valera Pharmaceuticals in April 2007 has expanded its product portfolio, establishing it as an emerging leader in the areas of urology and men´s health.



Scope

Contains corporate strategy, value

chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

Indevus Pharmaceuticals is a biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and men´s health conditions.



The company´s marketed products are: Sanctura for the treatment of overactive bladder; Delatestryl for treating hypogonadism in men; Supprelin-LA for the treatment of central precocious puberty; and Vantas indicated in hormone suppression therapy for advanced prostate cancer.



Indevus Pharmaceuticals derives its revenues from contract and license fees and product revenues which include revenues from sales of products, commissions and royalties. The company obtains products and product candidates through acquisitions and licensing agreements with other pharmaceutical and biotechnology companies.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization